FDA Approves First Gene Therapy for Rare Metabolic Disease. Price Tag: $2.7 Million

The FDA on Wednesday approved the first-ever treatment for glycogen storage disease type Ia, a brutal genetic disorder that until now had zero drug options. Patients had one tool: raw cornstarch, eaten every few hours, forever.

GSDIa hits somewhere between 1,500 and 2,500 Americans, according to the FDA and drugmaker Ultragenyx. The disease knocks out an enzyme called glucose-6-phosphatase, which the liver needs to release stored sugar into the bloodstream between meals. Without it, blood sugar can crash hard enough to cause seizures or death.

The current fix is old-school and unforgiving. Patients eat slow-digesting cornstarch around the clock, including through the night, just to keep their blood sugar from bottoming out. David Weinstein, MD, a leading GSDIa expert, put it bluntly in a statement carried by MedPage Today and GlobeNewswire: "Even with meticulous adherence to this regimen, patients must be perfect. Any missed cornstarch puts patients at risk of severe hypoglycemia, seizures, and even death."

Genglycos, known chemically as pariglasgene brecaparvovec-opnr, is a one-time gene therapy. It uses a modified virus (an AAV8 vector) to deliver a working copy of the missing gene straight to the liver. The goal isn't managing symptoms. It's fixing the actual defect.

What the trial data shows, and what it doesn't

The approval rests on Ultragenyx's Phase 3 GlucoGene trial, 46 patients age 8 and up. After 48 weeks, patients on the therapy cut cornstarch intake by 41.1%, versus 10.2% on placebo, a statistically significant gap (p<0.001), according to MedPage Today and the FDA. On average, treated patients needed one fewer cornstarch dose a day.

That's real. It's also not a cure, and it's not proof the therapy prevents the seizures and organ damage GSDIa can cause long-term. The FDA approved Genglycos under its accelerated pathway, which means the agency is betting that "less cornstarch needed" reasonably predicts real clinical benefit, not that it's been proven yet. Ultragenyx has to keep collecting data, following 50 commercially treated patients for two years, according to pharmaphorum.

Karim Mikhail of the FDA's Center for Biologics Evaluation and Research called it "a great milestone," but the agency's own release is careful to flag that cornstarch reduction is a surrogate endpoint, not a confirmed outcome. That distinction matters. Surrogate-endpoint approvals have a mixed track record in gene therapy, and confirmatory trials sometimes fail to pan out.

The safety profile isn't nothing, either. Per MedPage Today's review of the label, at least 10% of treated patients had liver enzyme elevations (71%), nausea (38%), hypertriglyceridemia (29%), adrenal insufficiency (24%), Cushingoid features (14%), and anaphylaxis (10%). The drug carries warnings for hepatotoxicity, infusion reactions, and AAV-related tumor risk, and it's contraindicated in patients with severe liver fibrosis or cirrhosis, and in pregnancy.

The $2.7 million question

Reuters, via WTAQ and WSAU, reported the U.S. list price at $2.7 million per patient, with availability through qualified treatment centers within 30 to 60 days. Ultragenyx's stock jumped 7.5% in after-hours trading Wednesday on the news, per Reuters.

Nobody in the source material disputes that number or challenges it. A one-time treatment for a few thousand Americans, priced north of the median U.S. home, is now the industry standard for ultra-rare disease drugs. Insurers, state Medicaid programs, and self-funded employer plans will absorb that cost, and those costs get spread around eventually. Whether $2.7 million reflects actual value delivered or simply what a monopoly product for a disease with no competitors can extract is a fair question nobody in this coverage put to Ultragenyx directly.

Developing a one-time gene therapy for a disease affecting only a few thousand patients worldwide means there's no mass-market volume to spread R&D costs across. Ultragenyx also noted it's committing to years of follow-up data collection at its own expense. Eric Crombez, the company's chief medical officer, called the approval "the realization of the promise of a powerful new tool to deliver transformative medicines for people living with rare diseases."

Ultragenyx's first successful gene therapy approval comes after a rough patch. Reuters noted the FDA rejected the company's brain-disorder gene therapy in July 2025 over manufacturing questions. Genglycos becomes the company's fifth approved product overall, and it also earned Ultragenyx a Priority Review Voucher, per the company's GlobeNewswire release, a transferable credit that speeds future FDA reviews and can itself be sold for tens of millions of dollars.

Competition may eventually apply pressure on price. Reuters reported that Moderna and Beam Therapeutics both have early-stage GSDIa treatments in development. Neither has reached late-stage trials. Until one does, Genglycos has the market to itself, and patients with GSDIa have exactly one FDA-approved alternative to a lifetime of cornstarch: a single infusion that costs more than most Americans will earn in their lifetime.